natgillin/translations-raw huggingface dataset:
• Når du håndterer tabletterne: √ Del eller knæk ikke tabletterne. 
Do not break or grind the tablets.
Nephrotoksicitet (kreatinin) <1,25 X øvre normalgrænse 
Renal Toxicity (creatinine) <1.25 X upper normal limit
Macrogol, titandioxid (E171), lactosemonohydrat, triacetin, hypromellose, Sunset Yellow Lake (E110), rød jernoxid (E172) 
Macrogol, Titanium dioxide (E171), Lactose monohydrate, Triacetin, Hypromellose, Sunset Yellow Lake (E110), Iron oxide red (E172)
Bør ikke anvendes til hunde med maveblødning. 
Do not use in dogs with evidence of stomach bleeding.
Hver filmovertrukket tablet indeholder toceranibphosphat svarende til 10 mg, 15 mg eller 50 mg toceranib. 
Each film-coated tablet contains toceranib phosphate equivalent to 10 mg, 15 mg or 50 mg of toceranib.
• ALAT eller ASAT <3 gange øvre normalgrænse 
• ALT or AST <3 X upper normal limit
Ikke almindelige (flere end 1, men færre end 10 dyr af 1.000 behandlede dyr) 
Uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
DOSERINGSTABEL: PALLADIA TABLETTER VED 3,25 MG/KG LEGEMSVÆGT Hundens legemsvægt (kg) 
DOSING TABLE: PALLADIA TABLETS AT 3.25 MG/KG BODYWEIGHT
Macrogol, titandioxid (E171), lactosemonohydrat, triacetin, hypromellose, talcum, rød jernoxid (E172) 
Macrogol, Titanium dioxide (E171), Lactose monohydrate, Triacetin, Hypromellose, Talc, Iron oxide red (E172)
Kontakt din dyrlæge, hvis der er givet flere tabletter end der er ordineret. 
If more than the prescribed amount of tablets were given, contact your veterinarian.
Palladia 15 mg tabletter: 
Palladia 15 mg tablets:
Palladia 50 mg tabletter: 
Palladia 50 mg tablets:
Almindeligt forekommende bivirkninger med mindre alvorlig indvirkning inkluderer: lokaliseret eller generel smerte, kvalme, luft i tarmene, hurtig vejrtrækning, sygeligt forøget tørst, feber, urinvejsinfektion, øget galdefarvestof, øget kreatinin. 
Also seen commonly but with less severe effects, were localised or general pain, nausea, flatulence, tachypnea, polydipsia, fever, urinary tract infection, increased bilirubin, increased creatinine.
Filmovertræk: 
Excipients:
ATCvet-kode: QL01XE91 
Pharmacotherapeutic group: Antineoplastic Agents - Protein-kinase inhibitors ATC vet code: QL01XE91
• Tre hunde havde krampelignende aktivitet. 
• Three dogs had seizure-like activity; however, relation to treatment could not be established.
Andre alvorlige bivirkninger, som er almindeligt set (flere end 1, men færre end 10 dyr af 100 behandlede dyr) inkluderer: opkastning, diarré, spisevægring, sløvhed, væskemangel, vævshenfald af hud, feber, blod i afføring/blodig diarré/maveblødning og mavesår, kvalme, blodforgiftning, vægttab, øget alaninaminotransferase og nedsat indhold af røde blodlegemer i blodet. 
There were other side effects that are seen commonly (more than 1 but less than 10 animals in 100 animals treated) which have severe effects, these are vomiting, diarrhoea, anorexia, lethargy, dehydration, skin necrosis, fever, blood in faeces/haemorrhagic diarrhoea/gastrointestinal bleeding and ulcers, nausea, septicaemia, weight loss, increased alanine aminotransferase and decreased haematocrit.
• Diarré, neutropeni, vægttab, blod i fæces/hæmoragisk diarré/gastrointestinal blødning, anoreksi, letargi, opkastning; halthed/muskuloskeletale lidelser, dehydrering, dermatitis, pruritus; øget alaninaminotransferase, trombocytopeni, nedsat albumin-, nedsat hæmatokrit. 
• Diarrhoea, neutropenia, weight loss, blood in faeces/hemorrhagic diarrhoea/gastrointestinal bleeding, anorexia, lethargy, vomiting; lameness / musculoskeletal disorder, dehydration, dermatitis, pruritus; increased alanine aminotransferase, thrombocytopenia, decreased albumin, decreased haematocrit.
• Opkastning, diarré, anoreksi, letargi, dehydrering, pyreksi, blod i fæces/hæmoragisk diarré/gastrointestinal blødning, duodenalsår, kvalme, septikæmi, hudnekrose, vægttab; øget alaninaminotransferase, nedsat hæmatokrit. 
• Vomiting, diarrhoea, anorexia, lethargy, dehydration, pyrexia, blood in faeces/haemorrhagic diarrhoea/gastrointestinal bleeding, duodenal ulceration, nausea, septicaemia, skin necrosis, weight loss; increased alanine aminotransferase, decreased haematocrit.
• Urinkvælstof i blodet <1,5 gange øvre normalgrænse 
• Blood urea nitrogen <1.5 X upper normal limit
Administration af Palladia skal ophøre og passende behandling iværksættes, hvis der er mistanke om gastrointestinal ulceration, uanset om det skyldes Palladia eller degranulering af mastcelletumorer. 
If gastrointestinal ulceration is suspected, whether or not due to Palladia or to mast cell tumour degranulation, stop the administration of Palladia and treat appropriately.
Afbryd behandling indtil >1,5 g/dl og de kliniske tegn er normaliseret. 
Discontinue treatment until >1.5 g/dl and clinical signs normal, then decrease dose by 0.5 mg/kg
Macrogol, titandioxid (E171), lactosemonohydrat, triacetin, hypromellose, indigocarmin Lake (E132) 
Tablet coating: Palladia 10 mg tablets: Macrogol, Titanium dioxide (E171), Lactose monohydrate, Triacetin, Hypromellose, Indigo Carmin Lake (E132)
• Der forekom yderligere to dødsfald. 
• There were two further deaths; however, relation to treatment could not be established.
Nogle meget almindelige (flere end 1 ud af 10 behandlede dyr, der viser bivirkninger i løbet af en behandling) bivirkninger, som forbindes med Palladia-tabletter, er vægttab, diarré, neutropeni (lavt antal hvide blodlegemer), blod i afføring/blodig diarré/blødning i mavetarmkanalen, spisevægring, sløvhed, opkastning; halthed/forstyrrelser i bevægeapparatet, væskemangel, hudbetændelse, pruritus, (hudirritation, kløe); øget alaninaminotransferase, nedsat antal af blodplader, nedsat albumin, nedsat indhold af røde blodlegemer i blodet. 
Some very common (more than 1 in 10 animals treated displaying adverse reaction(s)) adverse reactions associated with Palladia tablets are weight loss, diarrhoea, neutropenia (low number of white blood cells), blood in faeces/ haemorrhagic diarrhoea/gastrointestinal bleeding, anorexia, lethargy, vomiting, lameness/ musculoskeletal disorder, dehydration, dermatitis, pruritus (skin irritation/scratching), increased alanine aminotransferase, thrombocytopenia, decreased albumin, decreased haematocrit.
Afbryd behandling indtil ≤3X øvre normalgrænse, seponer hepatoksiske lægemidler, hvis anvendt. 
Discontinue treatment until ≤3X upper normal limit,
Hver tablet indeholder 10 mg toceranib (som toceranibphosphat). 
Each tablet contains 10 mg toceranib (as toceranib phosphate).
Børn skal holdes væk fra fæces, urin eller opkast fra behandlede hunde. 
Keep children away from faeces, urine or vomit of treated dogs.
Hver tablet indeholder 50 mg toceranib (som toceranibphosphat). 
Each tablet contains 50 mg toceranib (as toceranib phosphate).
Hver tablet indeholder 15 mg toceranib (som toceranibphosphat). 
Each tablet contains 15 mg toceranib (as toceranib phosphate).
FREMSTILLER ANSVARLIG FOR BATCHFRIGIVELSE 
Manufacturer responsible for the batch release:
Palladia 10 mg tabletter til hund. 
Palladia 10 mg tablets for dogs.
Nedsæt derefter dosis med 0,5 mg/kg 
Discontinue treatment until >26%, then decrease dose by 0.5 mg/kg
Palladia 15 mg tabletter til hund. 
Palladia 15 mg tablets for dogs.
Palladia 50 mg tabletter til hund. 
Palladia 50 mg tablets for dogs.
Palladia 10 mg filmovertrukne tabletter til hund. 
Palladia 10 mg film-coated tablets for dogs.
Palladia 50 mg filmovertrukne tabletter til hund. 
Palladia 50 mg film-coated tablets for dogs.
Palladia 15 mg filmovertrukne tabletter til hund. 
Palladia 15 mg film-coated tablets for dogs.
Afbryd behandling indtil >1000/ µl og kliniske tegn er normaliseret. 
Discontinue treatment until >1000/µl and clinical signs normal, then decrease dose by 0.5 mg/kg
Nedsæt derefter dosis med 0,5 mg/kg. 
discontinue hepatotoxic drugs, if used, then decrease dose by 0.5 mg/kg
Afbryd behandling indtil <1,25 X øvre normalgrænse. 
Discontinue treatment until <1.25 X upper normal limit, then decrease dose by 0.5 mg/kg
Afbryd behandling og iværksæt understøttende behandling indtil der ikke længere er kliniske tegn på blod i afføring. 
Discontinue treatment and institute supportive care until resolution of all clinical signs of blood in stool, then decrease dose by 0.5 mg/kg
Palladia 10 mg filmovertrukne tabletter til hund Palladia 15 mg filmovertrukne tabletter til hund Palladia 50 mg filmovertrukne tabletter til hund 
NAME OF THE VETERINARY MEDICINAL PRODUCT Palladia 10 mg film-coated tablets for Dogs
• Brystkræft. 
• breast cancer.
Den fuldstændige EPAR for Docetaxel Teva Pharma findes på agenturets websted på ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports. 
The full EPAR for Docetaxel Teva Pharma can be found on the Agency's website ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
• Ikke-småcellet lungekræft. 
• non-small cell lung cancer.
Det kan også bruges sammen med cisplatin (et andet lægemiddel mod kræft) til patienter, der endnu ikke har fået nogen behandling mod deres kræftsygdom. 
It can also be used with cisplatin (another anticancer medicine) in patients who have not yet received any treatment for their cancer;
Dosis, behandlingsvarighed og anvendelse sammen med andre lægemidler afhænger af den pågældende kræfttype. 
The dose, duration of treatment and the medicines it is used with depend on the type of cancer being treated.
Det forklarer, hvordan Udvalget for Lægemidler til Mennesker (CHMP) vurderede lægemidlet og nåede frem til sin udtalelse til fordel for udstedelse af en markedsføringstilladelse og til sine anbefalinger om anvendelsesbetingelserne for Docetaxel Teva Pharma. 
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Docetaxel Teva Pharma.
• Prostatakræft, når hormonbehandling ikke virker på sygdommen. 
• prostate cancer, when the cancer does not respond to hormonal treatment.
Hvis du ønsker yderligere oplysninger om behandling med Docetaxel Teva Pharma, kan du læse indlægssedlen (også en del af denne EPAR) eller kontakte din læge eller dit apotek. 
For more information about treatment with Docetaxel Teva Pharma, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Docetaxel Teva Pharma må kun bruges, når neutrofiltallet (en type hvide blodlegemer) er mindst 1 500 celler/mm3. 
Docetaxel Teva Pharma is only used when the neutrophil count (the level of a type of white blood cell in the blood) is normal (at least 1,500 cells/mm3).
Det betyder, at Docetaxel Teva Pharma er identisk med et ‘referencelægemiddel', der allerede er godkendt i Den Europæiske Union, og som hedder Taxotere. 
This means that Docetaxel Teva Pharma is similar to a ‘reference medicine' already authorised in the European Union (EU) called Taxotere.
Docetaxel Teva Pharma gives hver tredje uge ved en infusion, der varer en time. 
Docetaxel Teva Pharma is given as a one-hour infusion every three weeks.
Docetaxel blokerer cellers evne til at nedbryde det indvendige celleskelet og dermed deres evne til at dele og formere sig. 
Docetaxel blocks the ability of cells to destroy the internal ‘skeleton' that allows them to divide and multiply.
Der krævedes ingen supplerende undersøgelser, eftersom Docetaxel Teva Pharma er et generisk lægemiddel, der indgives ved infusion og indeholder det samme aktive stof som referencelægemidlet Taxotere. 
No additional studies were needed as Docetaxel Teva Pharma is a generic medicine that is given by infusion and contains the same active substance as the reference medicine, Taxotere.
Docetaxel Teva Pharma anvendes sammen med prednison eller prednisolon (antiinflammatoriske lægemidler). 
Docetaxel Teva Pharma is used with prednisone or prednisolone (anti-inflammatory medicines);
Europa-Kommissionen udstedte en markedsføringstilladelse med gyldighed i hele Den Europæiske Union for Docetaxel Teva Pharma til Teva Pharma B.V. 
The European Commission granted a marketing authorisation valid throughout the European Union for Docetaxel Teva Pharma to Teva Pharma B.V. on 21 January 2011.
Docetaxel Teva Pharma anvendes til behandling af følgende kræftformer: 
Docetaxel Teva Pharma is used to treat the following types of cancer:
Da Docetaxel Teva Pharma er et generisk lægemiddel, anses benefit/risk-forholdet for at være det samme som for referencelægemidlet. 
Because Docetaxel Teva Pharma is a generic medicine, its benefits and risks are taken as being the same as the reference medicine's.
CHMP konkluderede, at Docetaxel Teva Pharma i overensstemmelse med EU's krav har vist sig at være sammenligneligt med Taxotere. 
The CHMP concluded that, in accordance with EU requirements, Docetaxel Teva Pharma has been shown to be comparable to Taxotere.
Virksomheden har fremlagt data fra faglitteraturen om docetaxe. 
The company has provided data from the published literature on docetaxel.
Docetaxel Teva Pharma er et lægemiddel, der indeholder det aktive stof docetaxel. 
Docetaxel Teva Pharma is a medicine that contains the active substance docetaxel.
Det aktive stof i Docetaxel Teva Pharma , docetaxel, tilhører en gruppe kræftlægemidler, der kaldes taxaner. 
The active substance in Docetaxel Teva Pharma, docetaxel, belongs to the group of anticancer medicines known as the taxanes.
Docetaxel Teva Pharma bør kun anvendes på afdelinger, der er specialiseret i kemoterapi, under overvågning af en læge, der er specialiseret i brug af kemoterapi. 
Docetaxel Teva Pharma should be used in wards specialising in chemotherapy (using medicines to treat cancer) under the supervision of a doctor who is qualified in the use of chemotherapy.
Docetaxel Teva Pharma er et ‘generisk lægemiddel'. 
Docetaxel Teva Pharma is a ‘generic medicine'.
Hvilken fordel og risiko er der forbundet med Docetaxel Teva Pharma? 
What are the benefits and risks of Docetaxel Teva Pharma?
Andre oplysninger om Docetaxel Teva Pharma: 
Other information about Docetaxel Teva Pharma
Docetaxel Teva Pharma er et koncentrat og en solvens, der blandes til en opløsning til infusion (dråbetilførsel i en vene). 
It is available as a concentrate and a solvent that are made up into a solution for infusion (drip into a vein).
Derudover fremlagde virksomheden undersøgelsesresultater til påvisning af, at kvaliteten af Docetaxel Teva Pharma infusionsopløsning svarer til kvaliteten af Taxotere. 
The company also showed that the Docetaxel Teva Pharma solution for infusion has comparable quality to that of Taxotere.
Docetaxel Teva Pharma kan bruges som eneste behandling, når andre lægemidler har været uden virkning. 
Docetaxel Teva Pharma can be used on its own after other treatments have failed.
Udvalget anbefalede udstedelse af markedsføringstilladelse for Docetaxel Teva Pharma. 
The Committee recommended that Docetaxel Teva Pharma be given marketing authorisation.
Hvorfor blev Docetaxel Teva Pharma godkendt? 
Why has Docetaxel Teva Pharma been approved?
Dette dokument er et sammendrag af den europæiske offentlige vurderingsrapport (EPAR). 
This is a summary of the European public assessment report (EPAR) for Docetaxel Teva Pharma.
Dagen før infusionen af Docetaxel Teva Pharma gives desuden dexamethason (et antiinflammatorisk lægemiddel) til patienten. 
Dexamethasone (an anti-inflammatory medicine) should also be given to the patient, starting on the day before the Docetaxel Teva Pharma infusion.
Hvordan blev Docetaxel Teva Pharma undersøgt? 
How has Docetaxel Teva Pharma been studied?
Hvad er Docetaxel Teva Pharma? 
What is Docetaxel Teva Pharma?
Hvordan anvendes Docetaxel Teva Pharma? 
How is Docetaxel Teva Pharma used?
Hvad anvendes Docetaxel Teva Pharma til? 
What is Docetaxel Teva Pharma used for?
Hvordan virker Docetaxel Teva Pharma? 
How does Docetaxel Teva Pharma work?
Derfor er disse rekommendationer kun tentative. 
Therefore, these recommendations are only tentative.
under 15* 
below 15*
Meget almindelig (>1/10); Almindelig (>1/100, <1/10); Ikke almindelig (>1/1,000 <1/100); Sjælden (>1/10,000 <1/1,000); Meget sjælden (<1/10,000) 
Very common (>1/10); Common (>1/100, <1/10); Uncommon (>1/1,000 <1/100); Rare (>1/10,000 <1/1,000); Very Rare (<1/10,000)
lot {nummer} 
Lot {number}
I alvorlige tilfælde kan dette medføre chok og dødsfald. 
In severe cases these may lead to shock and death.
over 6.0 (530)* 
above 60 (530)*
Standardrekommendationer 
Standard recommendations
Initial intravenøs bolus: 
Initial intravenous bolus:
- APTT skal kontrolleres mindst 1 gang daglig. 
- The aPTT should be monitored at least once daily.
undgå eller AFBRYD infusionen! 
avoid or STOP infusion !
Ingen specifik dosisjustering bliver foretaget for ældre patienter. 
No specific dosage adjustment is made for elderly patients.
- Pædiatrisk brug: Sikkerheden og effektiviteten til behandling af pædiatriske patienter er ikke blevet fastsat. 
- Paediatric Use: Safety and effectiveness in paediatric patients have not been established.
Dette gælder for en legemsvægt op til 110 kg. 
This is valid up to a body weight of 110 kg.
Initial dosering 
Initial dosage
Refludans optimale dosering under disse omstændigheder kendes ikke. 
The optimal dose regimen of Refludan in these circumstances is not known.
Alder alene bevirker en 7 % reduktion i clearance i aldersgruppen 30-70 år. 
Age alone causes a 7 % reduction in clearance from the age of 30 to 70 years.
Må ikke opbevare over 25º C. 
Do not store above 25C.
Størstedelen af forskellen i clearance mellem unge og ældre patienter skyldes forskelle i nyrefunktionen. 
The majority of the difference in clearance between young and elderly patients is due to the differences in renal function.
Den intravenøse injektion skal foretages langsomt. 
Intravenous injection is to be carried out slowly.
Almene anbefalinger - Rekonstituering og yderligere fortynding skal ske under sterile forhold. 
General recommendations - Reconstitution and further dilution must be carried out under sterile conditions.
Ca. 35 % af dosis udskilles uændret. 
About 35 % of the dose is excreted as unchanged compound.
Dosis afhænger sædvanligvis af patientens legemsvægt. 
Normally, the dosage depends on the patient's body weight.
BETINGELSER ELLER BEGRÆNSNINGER VEDRØRENDE SIKKER OG EFFEKTIV ANVENDELSE AF DET MEDICINSKE PRODUKT 
• CONDITIONS OR RESTRICTIONS WITH REGARD TO SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
Yderligere fortynding er nødvendig før brug. 
Further dilution is necessary prior to use.
Deres læge vil bestemme og kontrollere dosis og varigheden af behandlingen med Refludan afhængigt af Deres kliniske tilstand, legemsvægt og visse laboratorieværdier. 
Your doctor will determine and control the dosage and duration of your treatment with Refludan according to your clinical condition, your body weight, and certain laboratory values.
Den specifikke lepirudin-aktivitet er ca. 16.000 ATU/mg. 
The specific activity of lepirudin is approximately 16,000 ATU/mg.
Læs hele denne indlægsseddel grundigt, inden De begynder at bruge medicinen. 
Read all of this leaflet carefully before you start using this medicine.
Refludan fås i pakker på 1 eller 10 hætteglas. 
Refludan is available in packs of 1 or 10 vials.
Infusionshastigheden bør reduceres i henhold til tabel 1. 
The infusion rate must be reduced according to table 1.
APTT bør bestemmes igen 4 timer senere. 
The aPTT should be determined again 4 hours later.
På nuværende tidspunkt er der ingen tilgængelige informationer om brugen af Refludan under amning. 
There is currently no information available on the use of Refludan during lactation.
Dato for første markedsføringstilladelse: 13-03-97 Dato for sidste fornyelse af tilladelsen: 05-03-07 
Date of first authorisation: 13-03-1997 Date of last renewal: 05-03-2007
Graviditet og amning Spørg Deres læge eller apotek til råds, før De tager nogen form for medicin. 
Pregnancy and breast-feeding Ask your doctor or pharmacist for advice before taking any medicine.
Virkningsmekanismen er uafhængig af antithrombin III. 
Its mode of action is independent of antithrombin III.
Polypeptidet består af 65 aminosyrer og har en molekylevægt på 6979,5 Dalton. 
The polypeptide composed of 65 amino acids has a molecular weight of 6979.5 Dalton.
Der bør begyndes med den påtænkte vedligeholdelsesdosis uden forudgående belastningsdosis. 
The intended maintenance dose should be started with no loading dose.
Hvis De har en følelse af at effekten af Refludan er for stærk eller for svag, så tal med Deres læge eller apoteket herom. 
If you have the impression that the effect of Refludan is too strong or too weak, talk to your doctor or pharmacist.
Hovedparten af de bivirkninger, som patienterne fik under behandlingen med Refludan var generelt relateret til blødning (>1/10). 
The majority of undesirable effects experienced by patients treated with Refludan were generally related to bleeding (>1/10).
- Perfusionssprøjten skal skiftes senest hver 12. time efter infusionens påbegyndelse. 
- The perfusor syringe must be changed at least every 12 hours after the start of the infusion.
- Præparatet bør opvarmes til stuetemperatur inden administration. 
- The preparation should be warmed to room temperature before administration.
Hedeture Chok inklusive fatalt chok 
Hot flushes Shock including fatal shock
Når infusionen genoptages, bør infusionshastigheden nedsættes med 50 % (yderligere intravenøst bolus bør ikke administreres). 
At restart, the infusion speed should be decreased by 50 % (no additional intravenous bolus should be administered).
Justeret infusionshastighed [% af oprindelig dosis] 
Adjusted infusion rate [% of original dose]
Diagnosen skal verificeres med HIPAA (heparin induced platelet activation assay) eller tilsvarende test. 
The diagnosis should be confirmed by the HIPAA (heparin induced platelet activation assay) or an equivalent test.
Derfor bør alternative behandlingsmuligheder overvejes, før det besluttes at genbehandle patienter med Refludan. 
Therefore, alternative treatment options must be considered before the decision to re-expose a patient to Refludan.
Da risikoen for alvorlig blødning i disse tilfælde er betragtelig, skal Refludandosis reduceres væsentligt. 
Since the risk of serious bleeding is considerable in this situation, the dosage of Refludan should be substantially reduced.
Derfor er en stram kontrol af APTT nødvendig også ved længere behandling. 
Therefore, strict monitoring of aPTT is necessary also during prolonged therapy.
- Ældre: Patienter af en høj alder har en forøgede risiko for blødningskomplikationer med antikoagulation. 
- Elderly: Patients of advanced age have an increased risk of bleeding complications with anticoagulation.
Både ekskretion og metabolisme finder sted i nyrerne, og ca. 45 % af den indgivne dosis kan påvises i urinen. 
Both, excretion and metabolism take place in the kidney, and about 45 % of the dose administered is detectable in the urine.
Monitorering og justering af Refludandosering 
Monitoring and modification of the Refludan dosage regimen
Meget almindelige (mindst 1 ud af 10 patienter) - Blødning 
Very common (at least 1 in 10 people) - Bleeding
Denne indlægsseddel blev senest godkendt den {dato} 
This leaflet was last approved on {date}
Refludan er et antithrombotisk lægemiddel. 
Refludan is an antithrombotic medicine.
Hoste Stridor Dyspnø 
Cough Stridor Dyspnea
Da disse reaktioner er immunmedierede, kan patienter, der for nylig har været behandlet med hirudin eller hirudinanaloger, have en øget risiko. 
As these reactions are immune-mediated, patients with recent exposure to hirudin or hirudin analog may be at an increased risk.
REFLUDANS VIRKNING OG HVAD DE SKAL BRUGE DET TIL 
WHAT REFLUDAN IS AND WHAT IT IS USED FOR
- Generelt bør en infusionshastighed på 0,21 mg/kg/t ikke overstiges uden at undersøge om der er koagulationsanormaliteter, som muligvis forhindrer en passende APPT respons. 
- In general, an infusion rate of 0.21 mg/kg/hour should not be exceeded without checking for coagulation abnormalities which might be preventing an appropriate aPTT response.